Kazushige Kobayashi (pictured), a Tokyo-based managing director at Capital Dynamics and head of primaries coverage in Asia, is departing the firm after nearly 10 years.
He will remain as a senior advisor until the end of October, while exploring new opportunities within the private equity sphere. He is not leaving to take up a specific role with another group. Kobayashi...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.